<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ZOLPIDEM TARTRATEÂ - zolpidem tartrateÂ tablet, film coated, extended releaseÂ </strong><br>A-S Medication Solutions LLC<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">
<br>These highlights do not include all the information needed to use Zolpidem Tartrate safely and effectively. See full prescribing information for Zolpidem Tartrate.<br><br>Zolpidem Tartrate (Zolpidem Tartrate) TABLET, FILM COATED, EXTENDED RELEASE for ORAL use.<br>Initial U.S. Approval: 1992</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<p class="Highlighta"> Indications and Usage (<a href="#b8d73970-c2d9-42e0-bda5-7647bd4a84c0">1</a>)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  12/2007 </p>
<p class="Highlighta"> Warnings and Precautions </p>
<p class="Highlighta">Â Â Â Â Â Â  Severe anaphylactic and <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> (<a href="#b54ef3aa-d12a-4589-ba8c-8ba7d722742e">5.2</a>) 03/2007 </p>
<p class="Highlighta">Â Â Â Â Â  <span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">Abnormal thinking</span> and behavioral changes (<a href="#b4f4423a-a7ad-4b0d-88e7-3e84a7725126">5.3</a>)Â Â Â Â Â Â Â Â Â Â Â  03/2007 </p>
<p class="Highlighta">Â Â Â Â Â  Special populations (<a href="#b59dd0d5-5289-4301-996d-e5f2ca5efa2b">5.6</a>)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  04/2007 </p>
</div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta"> Zolpidem tartrate extended-release tablets, USP are indicated for the treatment of <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> characterized by difficulties with sleep onset and/or sleep maintenance. (<a href="#b8d73970-c2d9-42e0-bda5-7647bd4a84c0">1</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li> Adult dose: 12.5 mg once daily immediately before bedtime (<a href="#b628d354-f878-471b-a789-7671cbb8c9af">2.1</a>)</li>
<li> Elderly/debilitated/hepatically impaired patients: 6.25 mg once daily immediately before bedtime (<a href="#b97220af-cf2c-4f2e-a823-0561f16b6bde">2.2</a>)</li>
<li> Tablets to be swallowed whole, not to be crushed, divided or chewed.Â  Should not be taken with or immediately after a meal (<a href="#b860f8d5-96c0-4959-bc54-f70fe1f9998e">2.4</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta"> 6.25 mg and 12.5 mg extended-release tablets. Tablets <span class="Underline">not</span> scored (<a href="#b109981b-9752-473d-b754-c029710c7029">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta"> Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to zolpidem tartrate or to any of the inactive ingredients in the formulation (<a href="#b26d0c5c-29f9-4bb4-bf2e-af89c51f36ae">4</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li> Need to evaluate for co-morbid diagnoses: Revaluate if <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> persists after 7 to 10 days of use (<a href="#b81b7ac2-5d51-4e70-adbe-a0bc36947f1d">5.1</a>)</li>
<li> Severe anaphylactic/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>: <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span> and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> have been reported. Do not rechallenge if such reactions occur (<a href="#b54ef3aa-d12a-4589-ba8c-8ba7d722742e">5.2</a>)</li>
<li> <span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">Abnormal thinking</span>, behavioral changes, complex behaviors: May include â€œsleep-drivingâ€? and <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>. Immediately evaluate any new onset behavioral changes (<a href="#b4f4423a-a7ad-4b0d-88e7-3e84a7725126">5.3</a>)</li>
<li> <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span>: Worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or, suicidal thinking may occur.Â  Prescribe the least amount feasible to avoid <span class="product-label-link" type="condition" conceptid="4244894" conceptname="Intentional drug overdose">intentional overdose</span> (<a href="#b4f4423a-a7ad-4b0d-88e7-3e84a7725126">5.3</a>, <a href="#b59dd0d5-5289-4301-996d-e5f2ca5efa2b">5.6</a>)</li>
<li> Withdrawal effects: Symptoms may occur with rapid dose reduction or discontinuation (<a href="#b35d5426-ca49-47d0-919c-be8412f28020">5.4</a>, <a href="#b073af0b-35ca-4a66-86e7-7ed8d6d07f7c">9.2</a>)</li>
<li> CNS depressant effects: Use can impair alertness and motor coordination.Â  If used in combination with other CNS depressants, dose reductions may be needed due to additive effects. Do not use with alcohol (<a href="#b1d31a1c-5ed4-4a07-ac52-48047d7e7cab">2.3</a>, <a href="#ba902291-105b-4f1d-b5e4-0eff3c326f1f">5.5</a>)</li>
<li> Elderly/debilitated patients: Use lower dose due to impaired motor, cognitive performance and increased sensitivity (<a href="#b97220af-cf2c-4f2e-a823-0561f16b6bde">2.2</a>, <a href="#b59dd0d5-5289-4301-996d-e5f2ca5efa2b">5.6</a>)</li>
<li> Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, mild to moderate <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span>, impaired drug metabolism or hemodynamic responses, mild to moderate <span class="product-label-link" type="condition" conceptid="313459" conceptname="Sleep apnea">sleep apnea</span>: Use with caution and monitor closely (<a href="#b59dd0d5-5289-4301-996d-e5f2ca5efa2b">5.6</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta"> Most commonly observed adverse reactions (&gt; 10% in either elderly or adult patients) are: <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, next-day <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (<a href="#b0b03d97-3247-4cc0-94fb-f8b9d8d7f6e3">6.1</a>) </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Actavis at 1-800-432-8534 or FDA at 1-800-FDA-1088 or <span class="Bold Italics">www.fda.gov/medwatch.</span></span> </p>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul>
<li> CNS depressants: Enhanced CNS-depressant effects with combination use.Â  Use with alcohol causes additive psychomotor impairment (<a href="#b7d0ff28-8e05-4993-8cb3-f5bf70778a90">7.1</a>)</li>
<li> Imipramine: Decreased alertness observed with combination use. (<a href="#b7d0ff28-8e05-4993-8cb3-f5bf70778a90">7.1</a>)</li>
<li> Chlorpromazine: Impaired alertness and psychomotor performance observed with combination use (<a href="#b7d0ff28-8e05-4993-8cb3-f5bf70778a90">7.1</a>)</li>
<li> Rifampin: Combination use decreases exposure to and effects of zolpidem (<a href="#bea5c201-14a7-492d-9dbc-32524171026b">7.2</a>)</li>
<li> Ketoconazole: Combination use increases exposure to and effect of zolpidem (<a href="#bea5c201-14a7-492d-9dbc-32524171026b">7.2</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul>
<li> Pregnancy: Based on animal data, zolpidem may cause fetal harm. (<a href="#b6e7854e-f906-40b9-a9db-a0331480c84d">8.1</a>)</li>
<li> Nursing mothers: Zolpidem is excreted in human milk. (<a href="#b615d34e-8dbb-44d0-a554-a1a8aa7ef830">8.3</a>)</li>
<li> Pediatric use: Safety and effectiveness not established. <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">Hallucinations</span> (incidence rate 7.4%) and other psychiatric and/or nervous system adverse reactions were observed frequently in a study of pediatric patients with Attention-Deficit/<span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">Hyperactivity</span> Disorder (<a href="#b59dd0d5-5289-4301-996d-e5f2ca5efa2b">5.6</a>, <a href="#b71ea4c6-2e31-444f-8de3-92f1d9ab945f">8.4</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 4/2010</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"></a></h1>
<h1><a href="#section-1" class="toc"><span class="Bold">1Â  INDICATIONS &amp; USAGE
</span></a></h1>
<h1><a href="#section-2" class="toc"><span class="Bold">2Â  DOSAGE &amp; ADMINISTRATION
</span></a></h1>
<h2><a href="#section-2.1" class="toc"><span class="Bold">2.1 Dosage in adults
</span></a></h2>
<h2><a href="#section-2.2" class="toc"><span class="Bold">2.2 Special populations
</span></a></h2>
<h2><a href="#section-2.3" class="toc"><span class="Bold">2.3 Use with CNS depressants
</span></a></h2>
<h2><a href="#section-2.4" class="toc"><span class="Bold">2.4 Administration
</span></a></h2>
<h1><a href="#section-3" class="toc"><span class="Bold">3Â  DOSAGE FORMS &amp; STRENGTHS
</span></a></h1>
<h1><a href="#section-4" class="toc"><span class="Bold">4Â  CONTRAINDICATIONS
</span></a></h1>
<h1><a href="#section-5" class="toc"><span class="Bold">5Â  WARNINGS AND PRECAUTIONS
</span></a></h1>
<h2><a href="#section-5.1" class="toc"><span class="Bold">5.1 Need to evaluate for co-morbid diagnoses
</span></a></h2>
<h2><a href="#section-5.2" class="toc"><span class="Bold">5.2 Severe anaphylactic and <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>
</span></a></h2>
<h2><a href="#section-5.3" class="toc"><span class="Bold">5.3 <span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">Abnormal thinking</span> and behavioral changes
</span></a></h2>
<h2><a href="#section-5.4" class="toc"><span class="Bold">5.4 Withdrawal effects
</span></a></h2>
<h2><a href="#section-5.5" class="toc"><span class="Bold">5.5 CNS depressant effects
</span></a></h2>
<h2><a href="#section-5.6" class="toc"><span class="Bold">5.6 Special populations
</span></a></h2>
<h1><a href="#section-6" class="toc"><span class="Bold">6Â  ADVERSE REACTIONS
</span></a></h1>
<h2><a href="#section-6.1" class="toc"><span class="Bold">6.1 Clinical trials experience
</span></a></h2>
<h1><a href="#section-7" class="toc"><span class="Bold">7Â  DRUG INTERACTIONS
</span></a></h1>
<h2><a href="#section-7.1" class="toc"><span class="Bold">7.1 CNS-active drugs
</span></a></h2>
<h2><a href="#section-7.2" class="toc"><span class="Bold">7.2 Drugs that affect drug metabolism via cytochrome P450 
</span></a></h2>
<h2><a href="#section-7.3" class="toc"><span class="Bold">7.3 Other drugs with no interaction with zolpidem
</span></a></h2>
<h2><a href="#section-7.4" class="toc"><span class="Bold">7.4 Drug-laboratory test interactions 
</span></a></h2>
<h1><a href="#section-8" class="toc"><span class="Bold">8Â  USE IN SPECIFIC POPULATIONS
</span></a></h1>
<h2><a href="#section-8.1" class="toc"><span class="Bold">8.1 Pregnancy
</span></a></h2>
<h2><a href="#section-8.2" class="toc"><span class="Bold">8.2 Labor and delivery
</span></a></h2>
<h2><a href="#section-8.3" class="toc"><span class="Bold">8.3 Nursing mothers
</span></a></h2>
<h2><a href="#section-8.4" class="toc"><span class="Bold">8.4 Pediatric use
</span></a></h2>
<h2><a href="#section-8.5" class="toc"><span class="Bold">8.5 Geriatric use
</span></a></h2>
<h1><a href="#section-9" class="toc"><span class="Bold">9Â  DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span>
</span></a></h1>
<h2><a href="#section-9.1" class="toc"><span class="Bold">9.1 Controlled substance 
</span></a></h2>
<h2><a href="#section-9.2" class="toc"><span class="Bold">9.2 Abuse 
</span></a></h2>
<h2><a href="#section-9.3" class="toc"><span class="Bold">9.3 <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span>
</span></a></h2>
<h1><a href="#section-10" class="toc"><span class="Bold">10Â  OVERDOSAGE
</span></a></h1>
<h2><a href="#section-10.1" class="toc"><span class="Bold">10.1 Signs and symptoms 
</span></a></h2>
<h2><a href="#section-10.2" class="toc"><span class="Bold">10.2 Recommended treatment 
</span></a></h2>
<h1><a href="#section-11" class="toc"><span class="Bold">11Â  DESCRIPTION
</span></a></h1>
<h1><a href="#section-12" class="toc"><span class="Bold">12Â  CLINICAL PHARMACOLOGY
</span></a></h1>
<h2><a href="#section-12.1" class="toc"><span class="Bold">12.1Â  MECHANISM OF ACTION
</span></a></h2>
<h2><a href="#section-12.2" class="toc"><span class="Bold">12.3Â  PHARMACOKINETICS
</span></a></h2>
<h1><a href="#section-13" class="toc"><span class="Bold">13Â  NONCLINICAL TOXICOLOGY
</span></a></h1>
<h2><a href="#section-13.1" class="toc"><span class="Bold">13.1Â  CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY
</span></a></h2>
<h1><a href="#section-14" class="toc"><span class="Bold">14Â  CLINICAL STUDIES
</span></a></h1>
<h2><a href="#section-14.1" class="toc"><span class="Bold">14.1 Controlled clinical trials 
</span></a></h2>
<h2><a href="#section-14.2" class="toc"><span class="Bold">14.2 Studies pertinent to safety concerns for sedative/hypnotic drugs
</span></a></h2>
<h1><a href="#section-15" class="toc"><span class="Bold">16Â  HOW SUPPLIED/STORAGE AND HANDLING
</span></a></h1>
<h1><a href="#section-16" class="toc"><span class="Bold">17Â  PATIENT COUNSELING INFORMATION
</span></a></h1>
<h2><a href="#section-16.1" class="toc"><span class="Bold">17.1 Severe anaphylactic and <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>
</span></a></h2>
<h2><a href="#section-16.2" class="toc"><span class="Bold">17.2 Sleep-driving and other complex behaviors
</span></a></h2>
<h2><a href="#section-16.3" class="toc"><span class="Bold">17.3 Administration instructions
</span></a></h2>
<h2><a href="#section-16.4" class="toc"><span class="Bold">17.4 Medication Guide
</span></a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-1"></a><p></p>
<h1><span class="Bold">1Â  INDICATIONS &amp; USAGE
</span></h1>
<p class="First"></p>
<p>Zolpidem tartrate extended-release tablets are indicated for the treatment of <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> characterized by difficulties with sleep onset and/or sleep maintenance (as measured by wake time after sleep onset).</p>
<p>The clinical trials performed in support of efficacy were up to 3 weeks (using polysomnography measurement up to 2 weeks in both adult and elderly patients) and 24 weeks (using patient-reported assessment in adult patients only) in duration [see <a href="#b16b2f71-14df-46d5-894b-15fe02605c16">Clinical Studies (14)</a>].</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-2"></a><p></p>
<h1><span class="Bold">2Â  DOSAGE &amp; ADMINISTRATION
</span></h1>
<p class="First">The dose of zolpidem tartrate extended-release tablets should be individualized.</p>
<div class="Section">
<a name="section-2.1"></a><p></p>
<h2><span class="Bold">2.1 Dosage in adults
</span></h2>
<p class="First">The recommended dose of zolpidem tartrate extended-release tablets for adults is 12.5 mg once daily immediately before bedtime.Â  The total zolpidem tartrate extended-release tablets dose should not exceed 12.5 mg per day.</p>
</div>
<div class="Section">
<a name="section-2.2"></a><p></p>
<h2><span class="Bold">2.2 Special populations
</span></h2>
<p class="First">Elderly or debilitated patients may be especially sensitive to the effects of zolpidem tartrate. Patients with <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> do not clear the drug as rapidly as normals. The recommended dose of zolpidem tartrate extended-release tablets in both of these patient populations is 6.25 mg once daily immediately before bedtime [see <a href="#b59dd0d5-5289-4301-996d-e5f2ca5efa2b">Warnings and Precautions (5.6)</a>].</p>
</div>
<div class="Section">
<a name="section-2.3"></a><p></p>
<h2><span class="Bold">2.3 Use with CNS depressants
</span></h2>
<p class="First">Dosage adjustments may be necessary when zolpidem tartrate extended-release tablets are combined with other CNS depressant drugs because of the potentially additive effects [see <a href="#ba902291-105b-4f1d-b5e4-0eff3c326f1f">Warnings and Precautions (5.5)</a>].</p>
</div>
<div class="Section">
<a name="section-2.4"></a><p></p>
<h2><span class="Bold">2.4 Administration
</span></h2>
<p class="First">Zolpidem tartrate extended-release tablets should be swallowed whole, and not be divided, crushed, or chewed. The effect of zolpidem tartrate extended-release tablets may be slowed by ingestion with or immediately after a meal.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="section-3"></a><p></p>
<h1><span class="Bold">3Â  DOSAGE FORMS &amp; STRENGTHS
</span></h1>
<p class="First"></p>
<p>Zolpidem tartrate extended-release tablets, USP are available as extended-release tablets containing 6.25 mg or 12.5 mg of zolpidem tartrate, USP for oral administration.Â  Tablets are not scored.</p>
<p>Zolpidem tartrate extended-release tablets, USP 6.25 mg, are coated, white, round, bi-convex and debossed with A2 on one side.</p>
<p>Zolpidem tartrate extended-release tablets, USP 12.5 mg, are coated, yellow, round, bi-convex and debossed with A1 on one side.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<h1><span class="Bold">4Â  CONTRAINDICATIONS
</span></h1>
<p class="First"></p>
<p>Zolpidem tartrate extended-release tablets are contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to zolpidem tartrate or to any of the inactive ingredients in the formulation.Â  Observed reactions include <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> and <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> [see <a href="#b54ef3aa-d12a-4589-ba8c-8ba7d722742e">Warnings and Precautions (5.2)</a>].</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="section-5"></a><p></p>
<h1><span class="Bold">5Â  WARNINGS AND PRECAUTIONS
</span></h1>
<div class="Section">
<a name="section-5.1"></a><p></p>
<h2><span class="Bold">5.1 Need to evaluate for co-morbid diagnoses
</span></h2>
<p class="First">Because <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep disturbances</span> may be the presenting manifestation of a physical and/or psychiatric disorder, symptomatic treatment of <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> should be initiated only after a careful evaluation of the patient. <span class="Bold">The failure of <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> to remit after 7 to 10 days of treatment may indicate the presence of a primary psychiatric and/or medical illness that should be evaluated.</span> Worsening of <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> or the emergence of new thinking or behavior abnormalities may be the consequence of an unrecognized psychiatric or physical disorder. Such findings have emerged during the course of treatment with sedative/hypnotic drugs, including zolpidem.</p>
</div>
<div class="Section">
<a name="section-5.2"></a><p></p>
<h2><span class="Bold">5.2 Severe anaphylactic and <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>
</span></h2>
<p class="First">Rare cases of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> involving the tongue, glottis or larynx have been reported in patients after taking the first or subsequent doses of sedative-hypnotics, including zolpidem.Â  Some patients have had additional symptoms such as <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, throat closing or <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> that suggest <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>.Â  Some patients have required medical therapy in the emergency department.Â  If <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> involves the throat, glottis or larynx, airway obstruction may occur and be fatal.Â  Patients who develop <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> after treatment with zolpidem should not be rechallenged with the drug.</p>
</div>
<div class="Section">
<a name="section-5.3"></a><p></p>
<h2><span class="Bold">5.3 <span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">Abnormal thinking</span> and behavioral changes
</span></h2>
<p class="First">A variety of <span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">abnormal thinking</span> and behavior changes have been reported to occur in association with the use of sedative/hypnotics. Some of these changes may be characterized by decreased inhibition (e.g. <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressiveness</span> and extroversion that seemed out of character), similar to effects produced by alcohol and other CNS depressants. Visual and <span class="product-label-link" type="condition" conceptid="4164151" conceptname="Auditory hallucinations">auditory hallucinations</span> have been reported as well as behavioral changes such as <span class="product-label-link" type="condition" conceptid="4092397" conceptname="Bizarre behavior">bizarre behavior</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span> and <span class="product-label-link" type="condition" conceptid="4085688" conceptname="Loss of identity">depersonalization</span>.Â  In controlled trials, &lt;1% of adults with <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> who received zolpidem reported <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>.Â  In a clinical trial, 7.4% of pediatric patients with <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> associated with attention-deficit/<span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span> disorder (<span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span>), who received zolpidem reported <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span> [see <a href="#bd747da5-2256-4da0-ae09-7b22675883c8">Use in Specific Populations (8.4)</a>].</p>
<p>Complex behaviors such as â€œsleep-drivingâ€? (i.e., driving while not fully awake after ingestion of a sedative-hypnotic, with <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">amnesia</span> for the event) have been reported with sedative-hypnotics, including zolpidem.Â  These events can occur in sedative-hypnotic-naÃ¯ve as well as sedative-hypnotic-experienced persons.Â  Although behaviors such as â€œsleep-drivingâ€? may occur with zolpidem tartrate extended-release tablets alone at therapeutic doses, the use of alcohol and other CNS depressants with zolpidem tartrate extended-release tablets appears to increase the risk of such behaviors, as does the use of zolpidem tartrate extended-release tablets at doses exceeding the maximum recommended dose.Â  Due to the risk to the patient and the community, discontinuation of zolpidem tartrate extended-release tablets should be strongly considered for patients who report a â€œsleep-drivingâ€? episode.Â  Other complex behaviors (e.g., preparing and eating food, making phone calls, or having sex) have been reported in patients who are not fully awake after taking a sedative-hypnotic.Â  As with â€œsleep-drivingâ€?, patients usually do not remember these events.Â  <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">Amnesia</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> and other neuro-<span class="product-label-link" type="condition" conceptid="4294810" conceptname="Psychiatric symptom">psychiatric symptoms</span> may occur unpredictably.</p>
<p>In primarily depressed patients, worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, including suicidal thoughts and actions (including <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">completed suicides</span>), have been reported in association with the use of sedative/hypnotics.</p>
<p>It can rarely be determined with certainty whether a particular instance of the abnormal behaviors listed above is drug induced, spontaneous in origin, or a result of an underlying psychiatric or physical disorder. Nonetheless, the emergence of any new behavioral sign or symptom of concern requires careful and immediate evaluation.</p>
</div>
<div class="Section">
<a name="section-5.4"></a><p></p>
<h2><span class="Bold">5.4 Withdrawal effects
</span></h2>
<p class="First">Following the rapid dose decrease or abrupt discontinuation of sedative/hypnotics, there have been reports of signs and symptoms similar to those associated with withdrawal from other CNS-depressant drugs [see <a href="#b968cacd-cf91-4dc3-9d0c-ab24ad3b56c1">Drug Abuse and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span> (9)]</a>.</p>
</div>
<div class="Section">
<a name="section-5.5"></a><p></p>
<h2><span class="Bold">5.5 CNS depressant effects
</span></h2>
<p class="First">Zolpidem tartrate extended-release tablets, like other sedative/hypnotic drugs, has CNS-depressant effects. <span class="Underline">Due to the rapid onset of action, zolpidem tartrate extended-release tablets should only be taken immediately prior to going to bed.</span> Patients should be cautioned against engaging in hazardous occupations requiring complete mental alertness or motor coordination such as operating machinery or driving a motor vehicle after ingesting the drug, including potential impairment of the performance of such activities that may occur the day following ingestion of Zolpidem Tartrate Extended-Release Tablets. Zolpidem tartrate extended-release tablets showed additive effects when combined with alcohol and should not be taken with alcohol. Patients should also be cautioned about possible combined effects with other CNS-depressant drugs. Dosage adjustments may be necessary when zolpidem tartrate extended-release tablets are administered with such agents because of the potentially additive effects.</p>
</div>
<div class="Section">
<a name="section-5.6"></a><p></p>
<h2><span class="Bold">5.6 Special populations
</span></h2>
<div class="Section">
<a name="section-5.6.1"></a><p></p>
<h3><span class="Bold Italics">Use in the elderly and/or debilitated patients: 
</span></h3>
<p class="First">Impaired motor and/or cognitive performance after repeated exposure or unusual sensitivity to sedative/hypnotic drugs is a concern in the treatment of elderly and/or debilitated patients. Therefore, the recommended zolpidem tartrate extended-release tablets dosage is 6.25 mg in such patients to decrease the possibility of side effects [see <a href="#b97220af-cf2c-4f2e-a823-0561f16b6bde">Dosage and Administration (2.2)</a>].Â  These patients should be closely monitored.</p>
</div>
<div class="Section">
<a name="section-5.6.2"></a><p></p>
<h3><span class="Bold Italics">Use in patients with concomitant illness: 
</span></h3>
<p class="First">Clinical experience with zolpidem tartrate extended-release tablets in patients with concomitant systemic illness is limited. Caution is advisable in using zolpidem tartrate extended-release tablets in patients with diseases or conditions that could affect metabolism or hemodynamic responses.</p>
<p>Although studies did not reveal respiratory depressant effects at hypnotic doses of zolpidem in normals or in patients with mild to moderate <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span> (<span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span>), a reduction in the Total Arousal Index together with a reduction in lowest oxygen saturation and increase in the times of oxygen desaturation below 80% and 90% was observed in patients with mild-to-moderate <span class="product-label-link" type="condition" conceptid="313459" conceptname="Sleep apnea">sleep apnea</span> when treated with an immediate-release formulation of zolpidem tartrate (10 mg) when compared to placebo. Since sedative/hypnotics have the capacity to depress respiratory drive, precautions should be taken if zolpidem tartrate extended-release tablets are prescribed to patients with compromised respiratory function.Â  Post-marketing reports of <span class="product-label-link" type="condition" conceptid="318459" conceptname="Respiratory insufficiency">respiratory insufficiency</span>, most of which involved patients with pre-existing respiratory impairment, have been received. Zolpidem tartrate extended-release tablets should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="313459" conceptname="Sleep apnea">sleep apnea syndrome</span> or <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>.</p>
<p>Data in end-stage <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> patients repeatedly treated with an immediate-release formulation of zolpidem tartrate (10 mg) did not demonstrate drug accumulation or alterations in pharmacokinetic parameters. No dosage adjustment in renally impaired patients is required; however, these patients should be closely monitored [see <a href="#b22fa9af-8244-46e4-8068-665db0a0aa6b">Clinical Pharmacology (12.3)</a>].</p>
<p>A study in subjects with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> did reveal prolonged elimination in this group; therefore, treatment should be initiated with zolpidem tartrate extended-release tablets 6.25 mg in patients with hepatic compromise, and they should be closely monitored [see <a href="#b97220af-cf2c-4f2e-a823-0561f16b6bde">Dosage and Administration (2.2)</a> and <a href="#b22fa9af-8244-46e4-8068-665db0a0aa6b">Clinical Pharmacology (12.3)</a>].</p>
</div>
<div class="Section">
<a name="section-5.6.3"></a><p></p>
<h3><span class="Bold Italics">Use in patients with <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>: 
</span></h3>
<p class="First">As with other sedative/hypnotic drugs, zolpidem tartrate extended-release tablets should be administered with caution to patients exhibiting signs or symptoms of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>. Suicidal tendencies may be present in such patients and protective measures may be required. Intentional overdosage is more common in this group of patients; therefore, the least amount of drug that is feasible should be prescribed for the patient at any one time.</p>
</div>
<div class="Section">
<a name="section-5.6.4"></a><p></p>
<h3><span class="Italics">Use in pediatric patients: 
</span></h3>
<p class="First">Safety and effectiveness of zolpidem has not been established in pediatric patients.Â  In an 8-week study in pediatric patients (age 6-17 years) with <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> associated with <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span> given an immediate-release oral solution of zolpidem tartrate, zolpidem did not decrease sleep latency compared to placebo.Â  <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">Hallucinations</span> were reported in 7.4% of the pediatric patients who received zolpidem; none of the pediatric patients who received placebo reported <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span> [see <a href="#b71ea4c6-2e31-444f-8de3-92f1d9ab945f">Use in Specific Populations (8.4)</a>].</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-6"></a><p></p>
<h1><span class="Bold">6Â  ADVERSE REACTIONS
</span></h1>
<p class="First"></p>
<p>The following serious adverse reactions are discussed in greater detail in other sections of the labeling:</p>
<ul class="Disc">
<li>Serious anaphylactic and <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> [see <a href="#b54ef3aa-d12a-4589-ba8c-8ba7d722742e">Warnings and Precautions (5.2)</a>]</li>
<li><span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">Abnormal thinking</span>, behavior changes, and complex behaviors [see <a href="#b4f4423a-a7ad-4b0d-88e7-3e84a7725126">Warnings and Precautions (5.3)</a>]</li>
<li>Withdrawal effects [see <a href="#b35d5426-ca49-47d0-919c-be8412f28020">Warnings and Precautions (5.4)</a>]</li>
<li>CNS-depressant effects [see <a href="#ba902291-105b-4f1d-b5e4-0eff3c326f1f">Warnings and Precautions (5.5)</a>]</li>
</ul>
<div class="Section">
<a name="section-6.1"></a><p></p>
<h2><span class="Bold">6.1 Clinical trials experience
</span></h2>
<div class="Section">
<a name="section-6.1.1"></a><p></p>
<h3><span class="Italics">Associated with discontinuation of treatment: 
</span></h3>
<p class="First">In 3-week clinical trials in adults and elderly patients (&gt;65 years), 3.5% (7/201) patients receiving zolpidem tartrate extended-release tablets 6.25 or 12.5 mg discontinued treatment due to an adverse reaction as compared to 0.9% (2/216) of patients on placebo.Â  The reaction most commonly associated with discontinuation in patients treated with zolpidem tartrate extended-release tablets was <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> (1%).</p>
<p>In a 6-month study in adult patients (18-64 years of age), 8.5% (57/669) of patients receiving zolpidem tartrate extended-release tablets 12.5 mg as compared to 4.6% on placebo (16/349) discontinued treatment due to an adverse reaction.Â  Reactions most commonly associated with discontinuation of zolpidem tartrate extended-release tablets included <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> (<span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span> or <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>) reported in 1.5% (10/669) of patients as compared to 0.3% (1/349) of patients on placebo, and <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> (<span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4114950" conceptname="Endogenous depression">major depression</span> or <span class="product-label-link" type="condition" conceptid="40546087" conceptname="Depressed mood">depressed mood</span>) reported in 1.5% (10/669) of patients as compared to 0.3% (1/349) of patients on placebo.</p>
<p>Data from a clinical study in which selective serotonin reuptake inhibitor- (SSRI-) treated patients were given zolpidem revealed that four of the seven discontinuations during double-blind treatment with zolpidem (n=95) were associated with impaired concentration, continuing or aggravated <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, and <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic reaction</span>; one patient treated with placebo (n =97) was discontinued after an <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">attempted suicide</span>.</p>
</div>
<div class="Section">
<a name="section-6.1.2"></a><p></p>
<h3><span class="Italics">Most commonly observed adverse reactions in controlled trials: 
</span></h3>
<p class="First">During treatment with zolpidem tartrate extended-release tablets in adults and elderly at daily doses of 12.5 mg and 6.25 mg, respectively, each for three weeks, the most commonly observed adverse reactions associated with the use of zolpidem tartrate extended-release tablets were <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, next-day <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>.</p>
<p>In the 6-month trial evaluating zolpidem tartrate extended-release tablets 12.5 mg, the adverse reaction profile was consistent with that reported in short-term trials, except for a higher incidence of <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> (6.3% for zolpidem tartrate extended-release tablets versus 2.6% for placebo).</p>
</div>
<div class="Section">
<a name="section-6.1.3"></a><p></p>
<h3><span class="Italics">Adverse reactions observed at an incidence of â‰¥1% in controlled trials: 
</span></h3>
<p class="First">The following tables enumerate treatment-emergent adverse reaction frequencies that were observed at an incidence equal to 1% or greater among patients with <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> who received zolpidem tartrate extended-release tablets in placebo-controlled trials. Events reported by investigators were classified utilizing the MedDRA dictionary for the purpose of establishing event frequencies. The prescriber should be aware that these figures cannot be used to predict the incidence of side effects in the course of usual medical practice, in which patient characteristics and other factors differ from those that prevailed in these clinical trials. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigators involving related drug products and uses, since each group of drug trials is conducted under a different set of conditions.Â  However, the cited figures provide the physician with a basis for estimating the relative contribution of drug and nondrug factors to the incidence of side effects in the population studied.</p>
<p>The following tables were derived from results of two placebo-controlled efficacy trials involving zolpidem tartrate extended-release tablets. These trials involved patients with primary <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> who were treated for 3 weeks with zolpidem tartrate extended-release tablets at doses of 12.5 mg (Table 1) or 6.25 mg (Table 2), respectively.Â  The tables include only adverse reactions occurring at an incidence of at least 1% for zolpidem tartrate extended-release tablets patients and with an incidence greater than that seen in the placebo patients.</p>
<table frame="void" width="660">
<caption><span> Table 1. Incidence of Treatment-Emergent Adverse Reactions in a 3-week Placebo-Controlled Clinical Trial in Adults (percentage of patients reporting)</span></caption>
<thead>
<tr class="First">
<td align="center" valign="middle"></td>
<td align="center" valign="top"><span class="Bold">Zolpidem Tartrate</span></td>
<td align="center" valign="middle"></td>
</tr>
<tr>
<td align="center" valign="middle"><span class="Bold">Body System/Adverse </span></td>
<td align="center" valign="top"><span class="Bold">Extended-Release </span></td>
<td align="center" valign="middle"></td>
</tr>
<tr>
<td align="center" valign="middle"><span class="Bold">Reaction*</span></td>
<td align="center" valign="top"><span class="Bold">Tablets 12.5 mg</span></td>
<td align="center" valign="middle"><span class="Bold">Placebo</span></td>
</tr>
<tr class="Last">
<td align="center" valign="middle"></td>
<td align="center" valign="top"><span class="Bold">(N = 102)</span></td>
<td align="center" valign="middle"><span class="Bold">(N = 110)</span></td>
</tr>
</thead>
<tfoot>
<tr class="First"><td align="left" colspan="3" valign="top"> *Reactions reported by at least 1% of patients treated with zolpidem tartrate extended-release tablets and at greater frequency than in the placebo group. </td></tr>
<tr><td align="left" colspan="3" valign="top"> **<span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">Hallucinations</span> included <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span> NOS as well as visual and hypnogogic <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>. </td></tr>
<tr class="Last"><td align="left" colspan="3" valign="top">***Memory disorders include: <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">memory impairment</span>, <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">amnesia</span>, <span class="product-label-link" type="condition" conceptid="4229448" conceptname="Anterograde amnesia">anterograde amnesia</span>.</td></tr>
</tfoot>
<tbody>
<tr class="First">
<td align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestations</span></span></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Influenza</span></td>
<td align="center" valign="top">3</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">Gastroenteritis</span></td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="74052" conceptname="Labyrinthitis">Labyrinthitis</span></td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Bold">Metabolism and nutrition disorders</span></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Appetite disorder</td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Bold">Psychiatric disorders</span></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">Hallucinations</span>**</td>
<td align="center" valign="top">4</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">Disorientation</span></td>
<td align="center" valign="top">3</td>
<td align="center" valign="top">2</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span></td>
<td align="center" valign="top">2</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></td>
<td align="center" valign="top">2</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4160898" conceptname="Motor retardation">Psychomotor retardation</span></td>
<td align="center" valign="top">2</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4086349" conceptname="Binging">Binge eating</span></td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4085688" conceptname="Loss of identity">Depersonalization</span></td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4249261" conceptname="Disinhibition">Disinhibition</span></td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">Euphoric mood</span></td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">Mood swings</span></td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4136014" conceptname="Stress">Stress symptoms</span></td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span></span></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td align="center" valign="top">19</td>
<td align="center" valign="top">16</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td align="center" valign="top">15</td>
<td align="center" valign="top">2</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td align="center" valign="top">12</td>
<td align="center" valign="top">5</td>
</tr>
<tr>
<td align="left" valign="top">Memory disorders***</td>
<td align="center" valign="top">3</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4046907" conceptname="Dysequilibrium syndrome">Balance disorder</span></td>
<td align="center" valign="top">2</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4096147" conceptname="Poor concentration">Disturbance in attention</span></td>
<td align="center" valign="top">2</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">Hypoesthesia</span></td>
<td align="center" valign="top">2</td>
<td align="center" valign="top">1</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">Ataxia</span></td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span></td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye disorders</span></span></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">Visual disturbance</span></td>
<td align="center" valign="top">3</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="442546" conceptname="Red eye">Eye redness</span></td>
<td align="center" valign="top">2</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Vision blurred</span></td>
<td align="center" valign="top">2</td>
<td align="center" valign="top">1</td>
</tr>
<tr>
<td align="left" valign="top">Altered visual depth perception</td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4322318" conceptname="Eye strain">Asthenopia</span></td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Bold">Ear and labyrinth disorders</span></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">Vertigo</span></td>
<td align="center" valign="top">2</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">Tinnitus</span></td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Bold">Respiratory, thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">mediastinal disorders</span></span></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4038048" conceptname="Throat irritation">Throat irritation</span></td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span></span></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="center" valign="top">7</td>
<td align="center" valign="top">4</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td align="center" valign="top">2</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">Abdominal discomfort</span></td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="197981" conceptname="Abdominal tenderness">Abdominal tenderness</span></td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4048265" conceptname="Increased frequency of defecation">Frequent bowel movements</span></td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">Gastroesophageal reflux disease</span></td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Bold">Skin and subcutaneous tissue disorders</span></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4013892" conceptname="Crow's feet">Skin wrinkling</span></td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span></td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Bold">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">connective tissue disorders</span></span></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span></td>
<td align="center" valign="top">4</td>
<td align="center" valign="top">3</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></td>
<td align="center" valign="top">4</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="24134" conceptname="Neck pain">Neck pain</span></td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Bold">Reproductive system and <span class="product-label-link" type="condition" conceptid="77030" conceptname="Disorder of breast">breast disorders</span></span></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4302555" conceptname="Menorrhagia">Menorrhagia</span></td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Bold">General disorders and administration site conditions</span></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td align="center" valign="top">3</td>
<td align="center" valign="top">2</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4133044" conceptname="Chest discomfort">Chest discomfort</span></td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Bold">Investigations</span></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">Blood pressure increased</span></td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top">Body temperature increased</td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Bold">Injury, <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> and procedural complications</span></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">Contusion</span></td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Bold">Social circumstances</span></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr class="Last">
<td align="left" valign="top">Exposure to poisonous plant</td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">0</td>
</tr>
</tbody>
</table>
<table frame="void" width="595">
<caption><span> Table 2. Incidence of Treatment-Emergent Adverse Reactions in a 3-Week Placebo-Controlled Clinical Trial in ElderlyÂ  (percentage of patients reporting)</span></caption>
<thead>
<tr class="First">
<td align="center" valign="middle"></td>
<td align="center" valign="top"><span class="Bold">Zolpidem Tartrate</span></td>
<td align="center" valign="middle"></td>
</tr>
<tr>
<td align="center" valign="middle"><span class="Bold">Body System/Adverse</span></td>
<td align="center" valign="top"><span class="Bold">Extended-Release</span></td>
<td align="center" valign="middle"></td>
</tr>
<tr>
<td align="center" valign="middle"><span class="Bold">Reaction*</span></td>
<td align="center" valign="top"><span class="Bold">Tablets 6.25 mg</span></td>
<td align="center" valign="middle"><span class="Bold">Placebo</span></td>
</tr>
<tr class="Last">
<td align="center" valign="middle"></td>
<td align="center" valign="top"><span class="Bold">(N=99)</span></td>
<td align="center" valign="middle"><span class="Bold">(N=106)</span></td>
</tr>
</thead>
<tfoot>
<tr class="First"><td align="left" colspan="3" valign="top"> *Reactions reported by at least 1% of patients treated with zolpidem tartrate extended-release tablets and at greater frequency than in the placebo group. </td></tr>
<tr class="Last"><td align="left" colspan="3" valign="top"> **Memory disorders include: <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">memory impairment</span>, <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">amnesia</span>, <span class="product-label-link" type="condition" conceptid="4229448" conceptname="Anterograde amnesia">anterograde amnesia</span>. </td></tr>
</tfoot>
<tbody>
<tr class="First">
<td align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestations</span></span></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Nasopharyngitis</span></td>
<td align="center" valign="top">6</td>
<td align="center" valign="top">4</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4175297" conceptname="Lower respiratory tract infection">Lower respiratory tract infection</span></td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="380731" conceptname="Otitis externa">Otitis externa</span></td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infection</span></td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Bold">Psychiatric disorders</span></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span> </td>
<td align="center" valign="top">3</td>
<td align="center" valign="top">2</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4160898" conceptname="Motor retardation">Psychomotor retardation</span></td>
<td align="center" valign="top">2</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4071366" conceptname="Indifference">Apathy</span></td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="40546087" conceptname="Depressed mood">Depressed mood</span></td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span></span></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> </td>
<td align="center" valign="top">14</td>
<td align="center" valign="top">11</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td align="center" valign="top">8</td>
<td align="center" valign="top">3</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td align="center" valign="top">6</td>
<td align="center" valign="top">5</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4235891" conceptname="Burning sensation">Burning sensation</span></td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4250121" conceptname="Dizziness on standing up">Dizziness postural</span></td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top">Memory disorders**</td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4189159" conceptname="Muscle fibrillation">Muscle contractions involuntary</span></td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span></td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span></td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac disorders</span></span></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">Palpitations</span></td>
<td align="center" valign="top">2</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Bold">Respiratory, thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">mediastinal disorders</span> </span></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4010026" conceptname="Pharyngeal dryness">Dry throat</span></td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span></span></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span></td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Bold">Skin and subcutaneous tissue disorders</span></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span></td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Bold">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">connective tissue disorders</span></span></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></td>
<td align="center" valign="top">2</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Muscle cramp</span></td>
<td align="center" valign="top">2</td>
<td align="center" valign="top">1</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="24134" conceptname="Neck pain">Neck pain</span></td>
<td align="center" valign="top">2</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Bold">Renal and urinary disorders</span></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">Dysuria</span></td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Bold">Reproductive system and <span class="product-label-link" type="condition" conceptid="77030" conceptname="Disorder of breast">breast disorders</span></span></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4243181" conceptname="Vulvovaginal dryness">Vulvovaginal dryness</span></td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Bold">General disorders and administration site conditions</span></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4153160" conceptname="Influenza-like symptoms">Influenza like illness</span></td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span></td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Bold">Injury, <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> and procedural complications</span></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr class="Last">
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="24818" conceptname="Injury of neck">Neck injury</span></td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">0</td>
</tr>
</tbody>
</table>
</div>
<div class="Section">
<a name="section-6.1.4"></a><p></p>
<h3><span class="Bold Italics">Dose relationship for adverse reactions: 
</span></h3>
<p class="First">There is evidence from dose comparison trials suggesting a dose relationship for many of the adverse reactions associated with zolpidem use, particularly for certain CNS and gastrointestinal adverse events.</p>
</div>
<div class="Section">
<a name="section-6.1.5"></a><p></p>
<h3><span class="Bold Italics">Other adverse reactions observed during the premarketing evaluation of Zolpidem Tartrate Extended-Release Tablets: 
</span></h3>
<p class="First">Other treatment-emergent adverse reactions associated with participation in zolpidem tartrate extended-release tablets studies (those reported at frequencies of &lt;1%) were not different in nature or frequency to those seen in studies with immediate-release zolpidem tartrate, which are listed below.</p>
</div>
<div class="Section">
<a name="section-6.1.6"></a><p></p>
<h3><span class="Bold Italics">Adverse Events Observed During the Premarketing Evaluation of Immediate-Release Zolpidem Tartrate: 
</span></h3>
<p class="First">Immediate-release zolpidem tartrate was administered to 3,660 subjects in clinical trials throughout the U.S., Canada, and Europe. Treatment-emergent adverse events associated with clinical trial participation were recorded by clinical investigators using terminology of their own choosing. To provide a meaningful estimate of the proportion of individuals experiencing treatment-emergent adverse events, similar types of untoward events were grouped into a smaller number of standardized event categories and classified utilizing a modified World Health Organization (WHO) dictionary of preferred terms.</p>
<p>The frequencies presented, therefore, represent the proportions of the 3,660 individuals exposed to zolpidem, at all doses, who experienced an event of the type cited on at least one occasion while receiving zolpidem. All reported treatment-emergent adverse events are included, except those already listed in the table above of adverse events in placebo-controlled studies, those coding terms that are so general as to be uninformative, and those events where a drug cause was remote. It is important to emphasize that, although the events reported did occur during treatment with zolpidem tartrate tablets, they were not necessarily caused by it.</p>
<p>Adverse events are further classified within body system categories and enumerated in order of decreasing frequency using the following definitions: frequent adverse events are defined as those occurring in greater than 1/100 subjects; infrequent adverse events are those occurring in 1/100 to 1/1,000 patients; rare events are those occurring in less than 1/1,000 patients.</p>
<p><span class="Italics">Autonomic nervous system: </span>Frequent: <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>. Infrequent: increased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pallor</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>. Rare: abnormal accommodation, <span class="product-label-link" type="condition" conceptid="27587" conceptname="Disturbance of salivary secretion">altered saliva</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, increased saliva, tenesmus.</p>
<p><span class="Italics">Body as a whole: </span>Frequent<span class="Bold">: </span><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>. Infrequent<span class="Bold">: </span><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falling</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>. Rare: <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy aggravated</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic shock</span>, face <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flashes</span>, increased ESR, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="73754" conceptname="Restless legs">restless legs</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">rigors</span>, tolerance increased, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight decrease</span>.</p>
<p><span class="Italics">Cardiovascular system: </span>Infrequent: <span class="product-label-link" type="condition" conceptid="434056" conceptname="Late effects of cerebrovascular disease">cerebrovascular disorder</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>. Rare: <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>, <span class="product-label-link" type="condition" conceptid="314659" conceptname="Arteritis">arteritis</span>, <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">circulatory failure</span>, <span class="product-label-link" type="condition" conceptid="316429" conceptname="Premature beats">extrasystoles</span>, <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">hypertension aggravated</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">phlebitis</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="312349" conceptname="Venous varices">varicose veins</span>, <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span>.</p>
<p><span class="Italics">Central and peripheral nervous system: </span>Frequent: <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, drugged feeling, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>.Â  Infrequent: <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, decreased cognition, <span class="product-label-link" type="condition" conceptid="4071366" conceptname="Indifference">detached</span>, difficulty concentrating, <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">dysarthria</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional lability</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucination</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span>, <span class="product-label-link" type="condition" conceptid="4238753" conceptname="Optical illusion">illusion</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, sleeping (after daytime dosing), speech disorder, <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>. Rare: <span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">abnormal gait</span>, <span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">abnormal thinking</span>, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressive reaction</span>, <span class="product-label-link" type="condition" conceptid="4071366" conceptname="Indifference">apathy</span>, appetite increased, decreased libido, <span class="product-label-link" type="condition" conceptid="444401" conceptname="Delusions">delusion</span>, <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>, <span class="product-label-link" type="condition" conceptid="4085688" conceptname="Loss of identity">depersonalization</span>, <span class="product-label-link" type="condition" conceptid="440424" conceptname="Aphasia">dysphasia</span>, <span class="product-label-link" type="condition" conceptid="4075224" conceptname="Feeling bad">feeling strange</span>, <span class="product-label-link" type="condition" conceptid="4195475" conceptname="Behavior showing reduced motor activity">hypokinesia</span>, <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">hypotonia</span>, <span class="product-label-link" type="condition" conceptid="434889" conceptname="Dissociative disorder">hysteria</span>, intoxicated feeling, <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic reaction</span>, <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuralgia</span>, <span class="product-label-link" type="condition" conceptid="444252" conceptname="Neuritis">neuritis</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>, <span class="product-label-link" type="condition" conceptid="444243" conceptname="Neurosis">neurosis</span>, <span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attacks</span>, <span class="product-label-link" type="condition" conceptid="4154696" conceptname="Spastic paresis">paresis</span>, <span class="product-label-link" type="condition" conceptid="441838" conceptname="Personality disorder">personality disorder</span>, <span class="product-label-link" type="condition" conceptid="377535" conceptname="Sleep walking disorder">somnambulism</span>, <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">suicide attempts</span>, <span class="product-label-link" type="condition" conceptid="380534" conceptname="Tetany">tetany</span>, <span class="product-label-link" type="condition" conceptid="4089239" conceptname="Yawning">yawning</span>.</p>
<p><span class="Italics">Gastrointestinal system: </span>Frequent: <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="194475" conceptname="Hiccoughs">hiccup</span>.Â  Infrequent: <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>. Rare: <span class="product-label-link" type="condition" conceptid="201773" conceptname="Enteritis of small intestine">enteritis</span>, <span class="product-label-link" type="condition" conceptid="4152350" conceptname="Burping">eructation</span>, <span class="product-label-link" type="condition" conceptid="134681" conceptname="Diffuse spasm of esophagus">esophagospasm</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="194382" conceptname="External hemorrhoids">hemorrhoids</span>, <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">intestinal obstruction</span>, <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="133228" conceptname="Dental caries">tooth caries</span>.</p>
<p><span class="Italics">Hematologic and lymphatic system: </span>Rare: <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="4049428" conceptname="Hemoglobinemia">hyperhemoglobinemia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>,</p>
<p><span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>, <span class="product-label-link" type="condition" conceptid="4308125" conceptname="Macrocytic anemia">macrocytic anemia</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>.</p>
<p><span class="Italics">Immunologic system: </span>Infrequent: <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Rare: <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span> herpes simplex <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span>, <span class="product-label-link" type="condition" conceptid="380731" conceptname="Otitis externa">otitis externa</span>, <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span>.</p>
<p></p>
<p><span class="Italics">Liver and biliary system: </span>Infrequent: abnormal hepatic function, increased SGPT. Rare:</p>
<p><span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">bilirubinemia</span>, increased <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>.</p>
<p><span class="Italics">Metabolic and nutritional: </span>Infrequent: <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span>. Rare: <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span>, <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesteremia</span>, <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>, increased alkaline phosphatase, increased BUN, <span class="product-label-link" type="condition" conceptid="4177665" conceptname="Periorbital edema">periorbital edema</span>.</p>
<p><span class="Italics">Musculoskeletal system: </span>Infrequent: <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>. Rare: <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthrosis</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>, <span class="product-label-link" type="condition" conceptid="372409" conceptname="Sciatica">sciatica</span>, <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">tendinitis</span>.</p>
<p><span class="Italics">Reproductive system: </span>Infrequent: <span class="product-label-link" type="condition" conceptid="196471" conceptname="Puberty bleeding">menstrual disorder</span>, <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span>. Rare: <span class="product-label-link" type="condition" conceptid="4116072" conceptname="Fibroadenoma of breast">breast fibroadenosis</span>, breast neoplasm, <span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">breast pain</span>.</p>
<p><span class="Italics">Respiratory system: </span>Frequent: <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>.Â  Infrequent: <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>. Rare: <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>, <span class="product-label-link" type="condition" conceptid="24969" conceptname="Laryngitis">laryngitis</span>, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>.</p>
<p><span class="Italics">Skin and appendages: </span>Infrequent: <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>. Rare: <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, <span class="product-label-link" type="condition" conceptid="4032934" conceptname="Vesiculobullous rash">bullous eruption</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, <span class="product-label-link" type="condition" conceptid="4220002" conceptname="Furuncle">furunculosis</span>, injection-site <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity reaction</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>.</p>
<p><span class="Italics">Special senses: </span>Frequent: <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="4265433" conceptname="Visual impairment">vision abnormal</span>. Infrequent: <span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">eye irritation</span>, <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>, <span class="product-label-link" type="condition" conceptid="434944" conceptname="Scleritis">scleritis</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste perversion</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>. Rare: <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="373202" conceptname="Corneal ulcer">corneal ulceration</span>, <span class="product-label-link" type="condition" conceptid="379814" conceptname="Dislocation of lacrimal gland">lacrimation abnormal</span>, <span class="product-label-link" type="condition" conceptid="444223" conceptname="Sense of smell altered">parosmia</span>, <span class="product-label-link" type="condition" conceptid="4206763" conceptname="Photopsia">photopsia</span>.</p>
<p><span class="Italics">Urogenital system: </span>Frequent: <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>. Infrequent: <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">cystitis</span>, <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">urinary incontinence</span>. Rare: <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, micturition frequency, <span class="product-label-link" type="condition" conceptid="40304526" conceptname="Nocturia">nocturia</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, <span class="product-label-link" type="condition" conceptid="198199" conceptname="Pyelonephritis">pyelonephritis</span>, <span class="product-label-link" type="condition" conceptid="4167250" conceptname="Renal pain">renal pain</span>, <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7"></a><p></p>
<h1><span class="Bold">7Â  DRUG INTERACTIONS
</span></h1>
<div class="Section">
<a name="section-7.1"></a><p></p>
<h2><span class="Bold">7.1 CNS-active drugs
</span></h2>
<p class="First">Since the systematic evaluations of zolpidem in combination with other CNS-active drugs have been limited, careful consideration should be given to the pharmacology of any CNS-active drug to be used with zolpidem.Â  Any drug with CNS-depressant effects could potentially enhance the CNS-depressant effects of zolpidem.</p>
<p>An immediate-release formulation of zolpidem tartrate was evaluated in healthy subjects in single-dose interaction studies for several CNS drugs. Imipramine in combination with zolpidem produced no <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span> other than a 20% decrease in peak levels of imipramine, but there was an additive effect of decreased alertness. Similarly, chlorpromazine in combination with zolpidem produced no <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span>, but there was an additive effect of decreased alertness and psychomotor performance. A study involving haloperidol and zolpidem revealed no effect of haloperidol on the pharmacokinetics or pharmacodynamics of zolpidem. The lack of a drug interaction following single-dose administration does not predict a lack following chronic administration.</p>
<p>An additive effect on psychomotor performance between alcohol and zolpidem was demonstrated [see <a href="#ba902291-105b-4f1d-b5e4-0eff3c326f1f">Warnings and Precautions (5.5)</a>].</p>
<p>A single-dose interaction study with zolpidem 10 mg and fluoxetine 20 mg at steady-state levels in male volunteers did not demonstrate any clinically significant pharmacokinetic or <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacodynamic interactions</span>. When multiple doses of zolpidem and fluoxetine at steady-state concentrations were evaluated in healthy females, the only significant change was a 17% increase in the zolpidem half-life. There was no evidence of an additive effect in psychomotor performance.</p>
<p>Following five consecutive nightly doses of zolpidem 10 mg in the presence of sertraline 50 mg (17 consecutive daily doses, at 7:00 am, in healthy female volunteers), zolpidem C<span class="Sub">max</span> was significantly higher (43%) and T<span class="Sub">max </span>was significantly decreased (53%). Pharmacokinetics of sertraline and N-desmethylsertraline were unaffected by zolpidem.</p>
</div>
<div class="Section">
<a name="section-7.2"></a><p></p>
<h2><span class="Bold">7.2 Drugs that affect drug metabolism via cytochrome P450 
</span></h2>
<p class="First">Some compounds known to inhibit CYP3A may increase exposure to zolpidem.Â  The effect of inhibitors of other P450 enzymes has not been carefully evaluated.</p>
<p>A randomized, double-blind, crossover interaction study in ten healthy volunteers between itraconazole (200 mg once daily for 4 days) and a single dose of zolpidem (10 mg) given 5 hours after the last dose of itraconazole resulted in a 34% increase in AUC<span class="Sub">0-âˆž</span> of zolpidem. There were no significant pharmacodynamic effects of zolpidem on subjective <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, postural sway, or psychomotor performance.</p>
<p>A randomized, placebo-controlled, crossover interaction study in eight healthy female subjects between five consecutive daily doses of rifampin (600 mg) and a single dose of an immediate-release formulation of zolpidem tartrate (20 mg) given 17 hours after the last dose of rifampin showed significant reductions of the AUC (â€“73%), C<span class="Sub">max</span> (â€“58%), and T<span class="Sub">1/2</span> (â€“36%) of zolpidem together with significant reductions in the pharmacodynamic effects of zolpidem.</p>
<p>A randomized double-blind crossover interaction study in twelve healthy subjects showed that co-administration of a single 5 mg dose of immediate-release zolpidem tartrate with ketoconazole, a potent CYP3A4 inhibitor, given as 200 mg twice daily for 2 days increased C<span class="Sub">max </span>of zolpidem by a factor of 1.3 and increased the total AUC of zolpidem by a factor of 1.7 compared to zolpidem alone and prolonged the elimination half-life by approximately 30% along with an increase in the pharmacodynamic effects of zolpidem.Â  Caution should be used when ketoconazole is given with zolpidem and consideration should be given to using a lower dose of zolpidem when ketoconazole and zolpidem are given together.Â  Patients should be advised that use of zolpidem tartrate extended-release tablets with ketoconazole may enhance the sedative effects.</p>
</div>
<div class="Section">
<a name="section-7.3"></a><p></p>
<h2><span class="Bold">7.3 Other drugs with no interaction with zolpidem
</span></h2>
<p class="First">A study involving cimetidine/zolpidem and ranitidine/zolpidem combinations revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of zolpidem.</p>
<p>Zolpidem had no effect on digoxin pharmacokinetics and did not affect <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time when given with warfarin in normal subjects.</p>
</div>
<div class="Section">
<a name="section-7.4"></a><p></p>
<h2><span class="Bold">7.4 Drug-laboratory test interactions 
</span></h2>
<p class="First">Zolpidem is not known to interfere with commonly employed clinical laboratory tests. In addition, clinical data indicate that zolpidem does not cross-react with benzodiazepines, opiates, barbiturates, cocaine, cannabinoids, or amphetamines in two standard <span class="product-label-link" type="condition" conceptid="4215138" conceptname="Drug screening test">urine drug screens</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="section-8"></a><p></p>
<h1><span class="Bold">8Â  USE IN SPECIFIC POPULATIONS
</span></h1>
<div class="Section">
<a name="section-8.1"></a><p></p>
<h2><span class="Bold">8.1 Pregnancy
</span></h2>
<p class="First"><span class="Italics">Pregnancy Category C</span></p>
<p>There are no adequate and well-controlled studies of zolpidem tartrate extended-release tablets in pregnant women. Zolpidem tartrate extended-release tablets should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
<p>Administration of zolpidem to pregnant rats and rabbits resulted in adverse effects on offspring development at doses greater than the zolpidem tartrate extended-release tablets maximum recommended human dose (MRHD) of 12.5 mg/day (approximately 10 mg/day zolpidem base); however, <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> was not observed.</p>
<p>When zolpidem was administered at oral doses of 4, 20, and 100 mg base/kg (approximately 4, 20 and 100 times the MRHD on a mg/m<span class="Sup">2</span> basis) to pregnant rats during the period of organogenesis, dose-related decreases in fetal skull ossification occurred at all but the lowest dose, which is approximately 4 times the MRHD on a mg/m<span class="Sup">2</span> basis. In rabbits treated during organogenesis with zolpidem at oral doses of 1, 4, and 16 mg base/kg (approximately 2, 8 and 30 times the MRHD on a mg/m<span class="Sup">2</span> basis), increased embryo-<span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal death</span> and incomplete fetal skeletal ossification occurred at the highest dose. The no-effect dose for embryo-fetal toxicity in rabbits is approximately 8 times the MRHD on a mg/m<span class="Sup">2</span> basis. Administration of zolpidem to rats at oral doses of 4, 20, and 100 mg base/kg (approximately 4, 20 and 100 times the MRHD on a mg/m<span class="Sup">2</span> basis) during the latter part of pregnancy and throughout lactation produced decreased offspring growth and survival at all but the lowest dose, which is approximately 4 times the MRHD on a mg/m<span class="Sup">2</span> basis.</p>
<p><span class="Bold Italics">Neonatal complications</span></p>
<p>Studies in children to assess the effects of prenatal exposure to zolpidem have not been conducted; however, cases of severe <span class="product-label-link" type="condition" conceptid="4318857" conceptname="Neonatal respiratory depression">neonatal respiratory depression</span> have been reported when zolpidem was used at the end of pregnancy, especially when taken with other CNS depressants. Children born to mothers taking sedative-hypnotic drugs may be at some risk for withdrawal symptoms during the postnatal period. Neonatal <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">flaccidity</span> has also been reported in infants born to mothers who received sedative-hypnotic drugs during pregnancy.</p>
</div>
<div class="Section">
<a name="section-8.2"></a><p></p>
<h2><span class="Bold">8.2 Labor and delivery
</span></h2>
<p class="First">Zolpidem tartrate extended-release tablets have no established use in labor and delivery. [see <a href="#b6e7854e-f906-40b9-a9db-a0331480c84d">Pregnancy (8.1)</a>].</p>
</div>
<div class="Section">
<a name="section-8.3"></a><p></p>
<h2><span class="Bold">8.3 Nursing mothers
</span></h2>
<p class="First">Zolpidem is excreted in human milk. Studies in lactating mothers indicate that the half-life of zolpidem is similar to that in non-lactating women (2.6 Â± 0.3 hr). The effect of zolpidem on the nursing infant is not known. Caution should be exercised when the zolpidem tartrate extended-release tablets is administered to a nursing woman.</p>
</div>
<div class="Section">
<a name="section-8.4"></a><p></p>
<h2><span class="Bold">8.4 Pediatric use
</span></h2>
<p class="First">Safety and effectiveness of zolpidem have not been established in pediatric patients.</p>
<p>In an 8-week controlled study, 201 pediatric patients (aged 6-17 years) with <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> associated with attention-deficit/<span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span> disorder (90% of the patients were using psychoanaleptics), were treated with an oral solution of zolpidem (n=136), or placebo (n=65).Â  Zolpidem did not significantly decrease latency to persistent sleep, compared to placebo, as measured by polysomnography after 4 weeks of treatment.Â  Psychiatric and <span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">nervous system disorders</span> comprised the most frequent (&gt;5%) treatment emergent adverse reactions observed with zolpidem versus placebo and included <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (23.5% vs. 1.5%), <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (12.5% vs. 9.2%), and <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span> (7.4% vs. 0%) [see <a href="#b59dd0d5-5289-4301-996d-e5f2ca5efa2b">Warnings and Precautions (5.6)</a>].Â  Ten patients on zolpidem (7.4%) discontinued treatment due to an adverse reaction.</p>
<p>FDA has not required pediatric studies of zolpidem tartrate extended-release tablets in the pediatric population based on these efficacy and safety findings.</p>
</div>
<div class="Section">
<a name="section-8.5"></a><p></p>
<h2><span class="Bold">8.5 Geriatric use
</span></h2>
<p class="First">A total of 99 elderly (â‰¥65 years of age) received daily doses of 6.25 mg zolpidem tartrate extended-release tablets in a 3-week placebo-controlled study. The adverse reaction profile of zolpidem tartrate extended-release tablets 6.25 mg in this population was similar to that of zolpidem tartrate extended-release tablets 12.5 mg in younger adults (â‰¤ 64 years of age). <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> was reported in 8% of zolpidem tartrate extended-release tablets-treated patients compared with 3% of those treated with placebo.</p>
<p>The dose of zolpidem tartrate extended-release tablets in elderly patients is 6.25 mg to minimize adverse effects related to impaired motor and/or cognitive performance and unusual sensitivity to sedative/hypnotic drugs [see <a href="#b59dd0d5-5289-4301-996d-e5f2ca5efa2b">Warnings and Precautions (5.6)</a>].</p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="section-9"></a><p></p>
<h1><span class="Bold">9Â  DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span>
</span></h1>
<div class="Section">
<a name="section-9.1"></a><p></p>
<h2><span class="Bold">9.1 Controlled substance 
</span></h2>
<p class="First">Zolpidem tartrate is classified as a Schedule IV controlled substance by federal regulation.</p>
</div>
<div class="Section">
<a name="section-9.2"></a><p></p>
<h2><span class="Bold">9.2 Abuse 
</span></h2>
<p class="First">Abuse and addiction are separate and distinct from physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> and tolerance.Â  Abuse is characterized by misuse of the drug for non-medical purposes, often in combination with other psychoactive substances.Â  Tolerance is a state of adaptation in which exposure to a drug induces changes that result in a diminution of one or more of the drug effects over time.Â  Tolerance may occur to both desired and undesired effects of drugs and may develop at different rates for different effects.</p>
<p>Addiction is a primary, chronic, neurobiological disease with genetic, psychosocial, and environmental factors influencing its development and manifestations.Â  It is characterized by behaviors that include one or more of the following:Â  impaired control over drug use, compulsive use, continued use despite harm, and craving.Â  <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">Drug addiction</span> is a treatable disease, using a multidisciplinary approach, but relapse is common.</p>
<p>Studies of abuse potential in former drug abusers found that the effects of single doses of zolpidem tartrate 40 mg were similar, but not identical, to diazepam 20 mg, while zolpidem tartrate 10 mg effects were difficult to distinguish from placebo.</p>
<p>Because persons with a history of addiction to, or abuse of, drugs or alcohol are at increased risk for misuse, abuse and addiction of zolpidem, they should be monitored carefully when receiving zolpidem or any other hypnotic.</p>
</div>
<div class="Section">
<a name="section-9.3"></a><p></p>
<h2><span class="Bold">9.3 <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span>
</span></h2>
<p class="First">Physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> is a state of adaptation that is manifested by a specific withdrawal syndrome that can be produced by abrupt cessation, rapid dose reduction, decreasing blood level of the drug, and/or administration of an antagonist.</p>
<p>Sedative/hypnotics have produced withdrawal signs and symptoms following abrupt discontinuation. These reported symptoms range from mild <span class="product-label-link" type="condition" conceptid="4148767" conceptname="Dysphoric mood">dysphoria</span> and <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> to a withdrawal syndrome that may include abdominal and <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>. The following adverse events, which are considered to meet the DSM-III-R criteria for uncomplicated sedative/hypnotic withdrawal, were reported during U.S. clinical trials following placebo substitution occurring within 48 hours following last zolpidem treatment: <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, uncontrolled <span class="product-label-link" type="condition" conceptid="4136768" conceptname="Crying">crying</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span>, <span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attack</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, and <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal discomfort</span>. These reported adverse events occurred at an incidence of 1% or less. However, available data cannot provide a reliable estimate of the incidence, if any, of <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> during treatment at recommended doses. Postmarketing reports of abuse, <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> and withdrawal have been received.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-10"></a><p></p>
<h1><span class="Bold">10Â  OVERDOSAGE
</span></h1>
<div class="Section">
<a name="section-10.1"></a><p></p>
<h2><span class="Bold">10.1 Signs and symptoms 
</span></h2>
<p class="First">In postmarketing experience of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with zolpidem tartrate alone, or in combination with CNS-depressant agents, impairment of consciousness ranging from <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> to <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, cardiovascular and/or respiratory compromise and fatal outcomes have been reported.</p>
</div>
<div class="Section">
<a name="section-10.2"></a><p></p>
<h2><span class="Bold">10.2 Recommended treatment 
</span></h2>
<p class="First">General symptomatic and supportive measures should be used along with immediate gastric lavage where appropriate. Intravenous fluids should be administered as needed. Zolpidemâ€™s sedative hypnotic effect was shown to be reduced by flumazenil and therefore may be useful; however, flumazenil administration may contribute to the appearance of neurological symptoms (<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>).Â  As in all cases of drug <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, respiration, pulse, blood pressure, and other appropriate signs should be monitored and general supportive measures employed. <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> and <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span> should be monitored and treated by appropriate medical intervention. Sedating drugs should be withheld following zolpidem overdosage, even if excitation occurs. The value of dialysis in the treatment of overdosage has not been determined, although hemodialysis studies in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> receiving therapeutic doses have demonstrated that zolpidem is not dialyzable.</p>
<p>As with the management of all overdosage, the possibility of multiple drug ingestion should be considered. The physician may wish to consider contacting a poison control center for up-to-date information on the management of hypnotic drug product overdosage.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-11"></a><p></p>
<h1><span class="Bold">11Â  DESCRIPTION
</span></h1>
<p class="First">Zolpidem tartrate extended-release tablets, USP contain zolpidem tartrate, a non-benzodiazepine hypnotic of the imidazopyridine class. Zolpidem tartrate extended-release tablets are available in 6.25 mg and 12.5 mg strength tablets for oral administration.</p>
<p>Chemically, zolpidem is N,N,6-trimethyl-2-p-tolylimidazo[1,2-a] pyridine-3-acetamide L-(+)-tartrate (2:1). It has the following structure:</p>
<div class="Figure"><img alt="6951d53d-figure-01" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a85400b5-1973-46bc-b092-681ac310f280&amp;name=6951d53d-figure-01.jpg"></div>
<p>Zolpidem tartrate, USP is a white to off-white crystalline powder that is sparingly soluble in water, alcohol, and propylene glycol. It has a molecular weight of 764.88.</p>
<p>Zolpidem tartrate extended-release tablets consist of a two-portion tablet: one portion that releases its drug content immediately and another portion that allows a delayed release of additional drug content. Zolpidem tartrate extended-release tablets contain the following inactive ingredients: anhydrous lactose, colloidal anhydrous silica, colloidal silicon dioxide, hypromellose, light anhydrous silicic acid, magnesium stearate, methacrylic acid copolymer, polyethylene glycol, povidone, silica, silicified microcrystalline cellulose, sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>, sodium lauryl sulfate, talc, tartaric acid, triethyl citrate, and titanium dioxide. Additionally, the 6.25 mg strength contains polyvinyl alcohol. The 12.5 mg strength also contains polydextrose, triacetin, and yellow iron oxide.</p>
<p>Dissolution test is pending.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-12"></a><p></p>
<h1><span class="Bold">12Â  CLINICAL PHARMACOLOGY
</span></h1>
<div class="Section" data-sectionCode="43679-0">
<a name="section-12.1"></a><p></p>
<h2><span class="Bold">12.1Â  MECHANISM OF ACTION
</span></h2>
<p class="First">Zolpidem, the active moiety of zolpidem tartrate, is a hypnotic agent with a chemical structure unrelated to benzodiazepines, barbiturates, or other drugs with known hypnotic properties. It interacts with a GABA-BZ receptor complex and shares some of the pharmacological properties of the benzodiazepines. In contrast to the benzodiazepines, which non-selectively bind to and activate all BZ receptor subtypes, zolpidem <span class="Italics">in vitro </span>binds the BZ<span class="Sub">1</span> receptor preferentially with a high affinity ratio of the Î±<span class="Sub">1</span>/Î±<span class="Sub">5</span> subunits. This selective binding of zolpidem on the BZ<span class="Sub">1</span> receptor is not absolute, but it may explain the relative absence of myorelaxant and anticonvulsant effects in animal studies as well as the preservation of deep sleep (stages 3 and 4) in human studies of zolpidem tartrate at hypnotic doses.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="section-12.2"></a><p></p>
<h2><span class="Bold">12.3Â  PHARMACOKINETICS
</span></h2>
<p class="First">Zolpidem tartrate extended-release tablets exhibit biphasic absorption characteristics, which results in rapid initial absorption from the gastrointestinal tract similar to zolpidem tartrate immediate-release, then provides extended plasma concentrations beyond three hours after administration. A study in 24 healthy male subjects was conducted to compare mean zolpidem plasma concentration-time profiles obtained after single oral administration of zolpidem tartrate extended-release tablets 12.5 mg and of an immediate-release formulation of zolpidem tartrate (10 mg). The terminal elimination half-life observed with zolpidem tartrate extended-release tablets (12.5 mg) was similar to that obtained with immediate-release zolpidem tartrate (10mg). The mean plasma concentration-time profiles are shown in Figure 1.</p>
<div class="Figure">
<img alt="6951d53d-figure-02" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a85400b5-1973-46bc-b092-681ac310f280&amp;name=6951d53d-figure-02.jpg"><p class="MultiMediaCaption"> Figure 1: Mean plasma concentration-time profiles for zolpidem tartrate extended-release tablets (12.5 mg) and immediate-release zolpidem tartrate (10 mg)</p>
</div>
<p>In adult and elderly patients treated with zolpidem tartrate extended-release tablets, there was no evidence of accumulation after repeated once-daily dosing for up to two weeks.</p>
<p><span class="Italics">Absorption:</span></p>
<p>Following administration of Zolpidem Tartrate Extended-Release Tablets, administered as a single 12.5 mg dose in healthy male adult subjects, the mean peak concentration (C<span class="Sub">max</span>) of zolpidem was 134 ng/mL (range: 68.9 to 197 ng/ml) occurring at a median time (T<span class="Sub">max</span>) of 1.5 hours. The mean AUC of zolpidem was 740 ngÂ·hr/mL (range: 295 to 1359 ngÂ·hr/mL).</p>
<p>A food-effect study in 45 healthy subjects compared the pharmacokinetics of zolpidem tartrate extended-release tablets 12.5 mg when administered while fasting or within 30 minutes after a meal. Results demonstrated that with food, mean AUC and Cmax were decreased by 23% and 30%, respectively, while median T<span class="Sub">max</span> was increased from 2 hours to 4 hours. The half-life was not changed. These results suggest that, for faster sleep onset, zolpidem tartrate extended-release tablets should not be administered with or immediately after a meal.</p>
<p><span class="Italics">Distribution:</span></p>
<p>Total protein binding was found to be 92.5 Â± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.</p>
<p><span class="Italics">Metabolism:</span></p>
<p>Zolpidem is converted to inactive metabolites that are eliminated primarily by renal excretion.</p>
<p><span class="Italics">Elimination:</span></p>
<p>When zolpidem tartrate extended-release tablets were administered as a single 12.5 mg dose in healthy male adult subjects, the mean zolpidem elimination half-life was 2.8 hours (range: 1.62 to 4.05 hr).</p>
<p><span class="Italics">Special Populations</span></p>
<p>Elderly:</p>
<p>In 24 elderly (â‰¥65 years) healthy subjects administered a single 6.25 mg dose of zolpidem tartrate extended-release tablets, the mean peak concentration (C<span class="Sub">max</span>) of zolpidem was 70.6 (range: 35.0 to 161) ng/mL occurring at a median time (T<span class="Sub">max</span>) of 2.0 hours. The mean AUC of zolpidem was 413 ngÂ·hr/mL (range: 124 to 1190) ngÂ·hr/mL and the mean elimination half-life was 2.9 hours (range: 1.59 to 5.50 hours).</p>
<p><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>:</p>
<p>Zolpidem tartrate extended-release tablets were not studied in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. The pharmacokinetics of an immediate-release formulation of zolpidem tartrate in eight patients with chronic <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> were compared to results in healthy subjects. Following a single 20-mg oral zolpidem tartrate dose, mean C<span class="Sub">max </span>and AUC were found to be two times (250 vs. 499 ng/mL) and five times (788 vs. 4,203 ngÂ·hr/mL) higher, respectively, in hepatically compromised patients.Â  T<span class="Sub">max</span> did not change. The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr). Dosing should be modified accordingly in patients with <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> [see <a href="#b97220af-cf2c-4f2e-a823-0561f16b6bde">Dosage and Administration (2.2)</a> and <a href="#b59dd0d5-5289-4301-996d-e5f2ca5efa2b">Warnings and Precautions (5.6)</a>].</p>
<p><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>:</p>
<p>Zolpidem tartrate extended-release tablets were not studied in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. The pharmacokinetics of an immediate-release formulation of zolpidem tartrate were studied in 11 patients with end-stage <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> (mean Cl<span class="Sub">Cr</span> = 6.5 Â± 1.5 mL/min) undergoing hemodialysis three times a week, who were dosed with zolpidem tartrate 10 mg orally each day for 14 or 21 days. No statistically significant differences were observed for C<span class="Sub">max</span>, T<span class="Sub">max</span>, half-life, and AUC between the first and last day of drug administration when baseline concentration adjustments were made. On day 1, C<span class="Sub">max</span> was 172 Â± 29 ng/mL (range: 46 to 344 ng/mL). After repeated dosing for 14 or 21 days, C<span class="Sub">max</span> was 203 Â± 32 ng/mL (range: 28 to 316 ng/mL). On day 1, T<span class="Sub">max</span> was 1.7 Â± 0.3 hr (range: 0.5 to 3 hr); after repeated dosing T<span class="Sub">max</span> was 0.8 Â± 0.2 hr (range: 0.5 to 2 hr). This variation is accounted for by noting that last-day serum sampling began 10 hours after the previous dose, rather than after 24 hours. This resulted in residual drug concentration and a shorter period to reach maximal serum concentration. On day 1, T<span class="Sub">1/2 </span>was 2.4 Â± 0.4 hr (range: 0.4 to 5.1 hr).Â  After repeated dosing, T<span class="Sub">1/2</span> was 2.5 Â± 0.4 hr (range: 0.7 to 4.2 hr). AUC was 796 Â± 159 ngÂ·hr/mL after the first dose and 818 Â± 170 ngÂ·hr/mL after repeated dosing. Zolpidem was not hemodialyzable. No accumulation of unchanged drug appeared after 14 or 21 days. Zolpidem pharmacokinetics were not significantly different in renally-impaired patients. No dosage adjustment is necessary in patients with compromised renal function. However, as a general precaution, these patients should be closely monitored.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="section-13"></a><p></p>
<h1><span class="Bold">13Â  NONCLINICAL TOXICOLOGY
</span></h1>
<div class="Section">
<a name="section-13.1"></a><p></p>
<h2><span class="Bold">13.1Â  CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY
</span></h2>
<p class="First"><span class="Italics"> Carcinogenesis: </span></p>
<p>Zolpidem was administered to mice and rats for 2 years at dietary dosages of 4, 18, and 80 mg base/kg. In mice, these doses are approximately 2, 9, and 40 times the maximum recommended human dose (MRHD) of 12.5 mg/day (10 mg zolpidem base) on mg/m<span class="Sup">2</span> basis. In rats, these doses are approximately 4, 18, and 80 times the MRHD on a mg/m<span class="Sup">2</span> basis. No evidence of carcinogenic potential was observed in mice. In rats, renal tumors (<span class="product-label-link" type="condition" conceptid="440358" conceptname="Lipoma">lipoma</span>, liposarcoma) were seen at the mid- and high doses.</p>
<p><span class="Italics">Mutagenesis</span>:</p>
<p>Zolpidem was negative in <span class="Italics">in vitro </span>(bacterial reverse mutation, mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>, and chromosomal aberration) and <span class="Italics">in vivo </span>(mouse micronucleus) genetic toxicology assays.</p>
<p><span class="Italics">Impairment of fertility</span>:</p>
<p>Oral administration of zolpidem (doses of 4, 20, and 100 mg base/kg or approximately 4, 20, and 100 times the MRHD on a mg/m<span class="Sup">2</span> basis) to rats prior to and during mating, and continuing in females through postpartum day 25, resulted in irregular estrus cycles and prolonged precoital intervals. The no-effect dose for these findings is approximately 20 times the MRHD on a mg/m<span class="Sup">2</span> basis. There was no impairment of fertility at any dose tested.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-14"></a><p></p>
<h1><span class="Bold">14Â  CLINICAL STUDIES
</span></h1>
<div class="Section">
<a name="section-14.1"></a><p></p>
<h2><span class="Bold">14.1 Controlled clinical trials 
</span></h2>
<p class="First">Zolpidem tartrate extended-release tablets were evaluated in three placebo-controlled studies for the treatment of patients with chronic primary <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> (as defined in the APA Diagnostic and Statistical Manual of <span class="product-label-link" type="condition" conceptid="432586" conceptname="Mental disorder">Mental Disorders</span>, DSM IV).</p>
<p>Adult outpatients (18-64 years) with primary <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> (N=212) were evaluated in a double-blind, randomized, parallel-group, 3-week trial comparing zolpidem tartrate extended-release tablets 12.5 mg and placebo. Zolpidem tartrate extended-release tablets 12.5 mg decreased wake time after sleep onset (WASO) for the first 7 hours during the first 2 nights and for the first 5 hours after 2 weeks of treatment. Zolpidem tartrate extended-release tablets 12.5 mg were superior to placebo on objective measures (polysomnography recordings) of sleep induction (by decreasing latency to persistent sleep [LPS]) during the first 2 nights of treatment and after 2 weeks of treatment. Zolpidem tartrate extended-release tablets 12.5 mg were also superior to placebo on the patient reported global impression regarding the aid to sleep after the first 2 nights and after 3 weeks of treatment.</p>
<p>Elderly outpatients (â‰¥65 years) with primary <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> (N=205) were evaluated in a double-blind, randomized, parallel-group, 3-week trial comparing zolpidem tartrate extended-release tablets 6.25 mg and placebo. Zolpidem tartrate extended-release tablets 6.25 mg decreased wake time after sleep onset (WASO) for the first 6 hours during the first 2 nights and the first 4 hours after 2 weeks of treatment. Zolpidem tartrate extended-release tablets 6.25 mg were superior to placebo on objective measures (polysomnography recordings) of sleep induction (by decreasing LPS) during the first 2 nights of treatment and after 2 weeks on treatment. Zolpidem tartrate extended-release tablets 6.25 mg were superior to placebo on the patient reported global impression regarding the aid to sleep after the first 2 nights and after 3 weeks of treatment.</p>
<p>In both studies, in patients treated with zolpidem tartrate xtended-Release Tablets, polysomnography showed increased <span class="product-label-link" type="condition" conceptid="4100068" conceptname="Wakefulness">wakefulness</span> at the end of the night compared to placebo-treated patients.</p>
<p>In a 24-week double-blind, placebo controlled, randomized study in adult outpatients (18-64 years) with primary <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> (N=1025), zolpidem tartrate extended-release tablets 12.5 mg administered as needed (3 to 7 nights per week) were superior to placebo over 24 weeks, on patient global impression regarding aid to sleep, and on patient-reported specific sleep parameters for sleep induction and sleep maintenance with no significant increased frequency of drug intake observed over time.</p>
</div>
<div class="Section">
<a name="section-14.2"></a><p></p>
<h2><span class="Bold">14.2 Studies pertinent to safety concerns for sedative/hypnotic drugs
</span></h2>
<p class="First"><span class="Italics">Next-day residual effects:</span> In five clinical studies [three controlled studies in adults (18-64 years of age) administered zolpidem tartrate extended-release tablets 12.5 mg and two controlled studies in the elderly (â‰¥ 65 years of age) administered zolpidem tartrate extended-release tablets 6.25 mg or 12.5 mg], the effect of zolpidem tartrate extended-release tablets on vigilance, memory, or motor function were assessed using neurocognitive tests. In these studies, no significant decrease in performance was observed eight hours after a nighttime dose. In addition, no evidence of next-day residual effects was detected with zolpidem tartrate extended-release tablets 12.5 mg and 6.25 mg using self-ratings of sedation.</p>
<p>During the 3-week studies, next-day <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> was reported by 15% of the adult patients who received 12.5 mg zolpidem tartrate extended-release tablets versus 2% of the placebo group; next-day <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> was reported by 6% of the elderly patients who received 6.25 mg zolpidem tartrate extended-release tablets versus 5% of the placebo group [see <a href="#be9d9b48-75cc-4f38-97cc-9263a2c2ad03">Adverse Reactions (6)</a>].Â  In a 6-month study, the overall incidence of next-day <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> was 5.7% in the zolpidem tartrate extended-release tablets group as compared to 2% in the placebo group.</p>
<p><span class="Italics">Rebound effects:</span> Rebound <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, defined as a dose-dependent worsening in sleep parameters (latency, sleep efficiency, and number of awakenings) compared with baseline following discontinuation of treatment, is observed with short- and intermediate-acting hypnotics. In the two 3-week placebo-controlled studies in patients with primary <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, a rebound effect was only observed on the first night after abrupt discontinuation of zolpidem tartrate extended-release tablets. On the second night, there was no worsening compared to baseline in the zolpidem tartrate extended-release tablets group.</p>
<p>In a 6-month placebo-controlled study in which zolpidem tartrate extended-release tablets were taken as needed (3 to 7 nights per week), within the first month a rebound effect was observed for Total Sleep Time (not for WASO) during the first night off medication.Â  After this first month period, no further rebound <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> was observed.Â  After final treatment discontinuation no rebound was observed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-15"></a><p></p>
<h1><span class="Bold">16Â  HOW SUPPLIED/STORAGE AND HANDLING
</span></h1>
<p class="First">Zolpidem tartrate extended-release tablets, USP 6.25 mg, are composed of two portions* and are coated, white, round, bi-convex, debossed with A2 on one side and supplied as:</p>
<p><span class="Bold">NDC Number 	Size</span></p>
<p>0228-3481-11 		bottle of 100</p>
<p>0228-3481-50 		bottle of 500</p>
<p><br>Each tablet contains 6.25 mg of zolpidem tartrate, USP.</p>
<p>Zolpidem tartrate extended-release tablets, USP 12.5-mg, are composed of two portions* and are coated, yellow, round, bi-convex, debossed with A1 on one side and supplied as:</p>
<p><span class="Bold">NDC Number 	Size</span></p>
<p>0228-3482-11 		bottle of 100</p>
<p>0228-3482-50 		bottle of 500</p>
<p>Each tablet contains 12.5 mg of zolpidem tartrate, USP.</p>
<p>*Portions are covered by the coating and are indistinguishable.</p>
<p>Store at 20Â° to 25Â°C (68Â° to 77Â°F) [See USP Controlled Room Temperature]</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-16"></a><p></p>
<h1><span class="Bold">17Â  PATIENT COUNSELING INFORMATION
</span></h1>
<p class="First">Prescribers or other healthcare professionals should inform patients, their families, and their caregivers about the benefits and risks associated with treatment with sedative-hypnotics, should counsel them in its appropriate use, and should instruct them to read the accompanying Medication Guide [see <a href="#b5b74e98-971d-4ad7-8093-9081977c8872">Medication Guide (17.4)</a>].</p>
<div class="Section">
<a name="section-16.1"></a><p></p>
<h2><span class="Bold">17.1 Severe anaphylactic and <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>
</span></h2>
<p class="First">Inform patients that severe anaphylactic and <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> have occurred with zolpidem.Â  Describe the signs/symptoms of these reactions and advise patients to seek medical attention immediately if any of them occur.</p>
</div>
<div class="Section">
<a name="section-16.2"></a><p></p>
<h2><span class="Bold">17.2 Sleep-driving and other complex behaviors
</span></h2>
<p class="First">There have been reports of people getting out of bed after taking a sedative-hypnotic and driving their cars while not fully awake, often with no memory of the event.Â  If a patient experiences such an episode, it should be reported to his or her doctor immediately, since â€œsleep-drivingâ€? can be dangerous.Â  This behavior is more likely to occur when zolpidem tartrate extended-release tablets are taken with alcohol or other central nervous system depressants [see <a href="#b4f4423a-a7ad-4b0d-88e7-3e84a7725126">Warnings and Precautions (5.3)</a>].Â  Other complex behaviors (e.g., preparing and eating food, making phone calls, or having sex) have been reported in patients who are not fully awake after taking a sedative-hypnotic.Â  As with â€œsleep-drivingâ€?, patients usually do not remember these events.</p>
<p>In addition, patients should be advised to report all concomitant medications to the prescriber.Â  Patients should be instructed to report events such as â€œsleep-drivingâ€? and other complex behaviors immediately to the prescriber.</p>
</div>
<div class="Section">
<a name="section-16.3"></a><p></p>
<h2><span class="Bold">17.3 Administration instructions
</span></h2>
<p class="First">Patients should be counseled to take zolpidem tartrate extended-release tablets right before they get into bed and only when they are able to stay in bed a full night (7-8 hours) before being active again.Â  Zolpidem tartrate extended-release tablets should not be crushed, divided, or chewed, and should not be taken with or immediately after a meal.Â  Advise patients NOT to take zolpidem tartrate extended-release tablets when drinking alcohol.</p>
<p><span class="Bold">Rx Only</span></p>
<p><span class="Bold"><br></span>Manufactured by:<br>Actavis Elizabeth LLC<br>200 Elmora Avenue<br>Elizabeth, NJ 07207 USA<br></p>
<p>Revised â€“ February 2011<br>40-9104</p>
</div>
<div class="Section">
<a name="section-16.4"></a><p></p>
<h2><span class="Bold">17.4 Medication Guide
</span></h2>
<p class="First"><span class="Bold">MEDICATION GUIDE</span></p>
<p><span class="Bold">ZOLPIDEM TARTRATE EXTENDED-RELEASE TABLETS, USP</span></p>
<p><span class="Bold">Rx Only</span></p>
<p>Read the Medication Guide that comes with zolpidem tartrate extended-release tablets before you start taking it and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking to your doctor about your medical condition or treatment.</p>
<p><span class="Bold">What is the most important information I should know about Zolpidem Tartrate Extended-Release Tablets?</span></p>
<p><span class="Bold">After taking zolpidem tartrate extended-release tablets, you may get up out of bed while not being fully awake and do an activity that you do not know you are doing. The next morning, you may not remember that you did anything during the night. </span>You have a higher chance for doing these activities if you drink alcohol or take other medicines that make you <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepy</span> with zolpidem tartrate extended-release tablets. Reported activities include:</p>
<ul class="Disc">
<li>driving a car ("sleep-driving")</li>
<li>making and eating food</li>
<li>talking on the phone</li>
<li>having sex</li>
<li>sleep-walking</li>
</ul>
<p><span class="Bold">Call your doctor right away if you find out that you have done any of the above activities after taking zolpidem tartrate extended-release tablets.</span></p>
<p><span class="Bold">Important:</span></p>
<p><span class="Bold">1.Â  Take zolpidem tartrate extended-release tablets exactly as prescribed</span></p>
<ul class="Disc">
<li>Do not take more zolpidem tartrate extended-release tablets than prescribed.</li>
<li>Take zolpidem tartrate extended-release tablets right before you get in bed, not sooner.</li>
</ul>
<p><span class="Bold">2.Â  Do not take zolpidem tartrate extended-release tablets if you:</span></p>
<ul class="Disc">
<li>drink alcohol</li>
<li>take other medicines that can make you <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepy</span>. Talk to your doctor about all of your medicines.Â  Your doctor will tell you if you can take zolpidem tartrate extended-release tablets with your other medicines.</li>
<li>cannot get a full nightâ€™s sleep</li>
</ul>
<p><span class="Bold">What are Zolpidem Tartrate Extended-Release Tablets?</span></p>
<p>Zolpidem tartrate extended-release tablets are a sedative-hypnotic (sleep) medicine. Zolpidem tartrate extended-release tablets are used in adults for the treatment of a <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep problem</span> called <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>. Symptoms of <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> include:</p>
<ul class="Disc">
<li>trouble <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falling</span> asleep</li>
<li>waking up often during the night</li>
</ul>
<p>Zolpidem tartrate extended-release tablets are not for children.</p>
</div>
</div>
<div class="Warning">
<a name="section-17"></a><p></p>
<h1><span class="Bold"></span></h1>
<p class="First">Zolpidem tartrate extended-release tablets are a federally controlled substance (C-IV) because it can be abused or lead to <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>. Keep zolpidem tartrate extended-release tablets in a safe place to prevent misuse and abuse. Selling or giving away zolpidem tartrate extended-release tablets may harm others, and is against the law. Tell your doctor if you have ever abused or have been dependent on alcohol, prescription medicines or street drugs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-17"></a><p></p>
<h1><span class="Bold"></span></h1>
<p class="First"><span class="Bold">Who should not take Zolpidem Tartrate Extended-Release Tablets?</span></p>
<p>Do not take zolpidem tartrate extended-release tablets if you are allergic to anything in it. See the end of this Medication Guide for a complete list of ingredients in zolpidem tartrate extended-release tablets.</p>
<p><span class="Bold">Zolpidem tartrate extended-release tablets may not be right for you. Before starting zolpidem tartrate extended-release tablets, tell your doctor about all of your health conditions, including if you:</span></p>
<ul class="Disc">
<li>have a history of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, mental illness, or suicidal thoughts</li>
<li>have a history of drug or <span class="product-label-link" type="condition" conceptid="433753" conceptname="Alcohol abuse">alcohol abuse</span> or addiction</li>
<li>have kidney or liver disease</li>
<li>have a <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">lung disease</span> or breathing problems</li>
<li>are pregnant, planning to become pregnant, or breastfeeding</li>
</ul>
<p>Tell your doctor about all of the medicines you take including prescription and nonprescription medicines, vitamins and herbal supplements. Medicines can interact with each other, sometimes causing serious side effects. <span class="Bold">Do not take zolpidem tartrate extended-release tablets with other medicines that can make you <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepy</span>.</span></p>
<p>Know the medicines you take. Keep a list of your medicines with you to show your doctor and pharmacist each time you get a new medicine.</p>
<p><span class="Bold">How should I take Zolpidem Tartrate Extended-Release Tablets?</span></p>
<ul class="Disc">
<li>Take zolpidem tartrate extended-release tablets exactly as prescribed. Do not take more zolpidem tartrate extended-release tablets than prescribed for you.</li>
<li><span class="Bold">Take zolpidem tartrate extended-release tablets right before you get into bed.</span></li>
<li><span class="Bold">Do not take zolpidem tartrate extended-release tablets unless you are able to stay in bed a full night (7-8 hours) before you must be active again.</span></li>
<li>Swallow zolpidem tartrate extended-release tablets whole. Do not chew or break the tablets. Tell your doctor if you cannot swallow tablets whole.</li>
<li>For faster sleep onset, zolpidem tartrate extended-release tablets should NOT be taken with or immediately after a meal.</li>
<li>Call your doctor if your <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> worsens or is not better within 7 to 10 days. This may mean that there is another condition causing your <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep problems</span>.</li>
<li>If you take too many zolpidem tartrate extended-release tablets or <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, call your doctor or poison control center right away, or get emergency treatment.</li>
</ul>
<p><span class="Bold">What are the possible side effects of Zolpidem Tartrate Extended-Release Tablets?</span></p>
<p><span class="Bold">Serious side effects of zolpidem tartrate extended-release tablets include:</span></p>
<ul class="Disc">
<li>
<span class="Bold">getting out of bed while not being fully awake and do an activity that you do not know you are doing. </span>(See â€œWhat is the most important information I should know about zolpidem tartrate extended-release tablets?â€?)</li>
<li>
<span class="Bold">abnormal thoughts and behavior. </span>Symptoms include more outgoing or <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressive behavior</span> than normal, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, and suicidal thoughts or actions.</li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">memory loss</span></span></li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span></span></li>
<li>
<span class="Bold">severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>. </span>Symptoms include <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the tongue or throat, trouble breathing, and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. Get emergency medical help if you get these symptoms after taking zolpidem tartrate extended-release tablets.</li>
</ul>
<p>Call your doctor for medical advice about side effects.Â  You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">Call your doctor right away if you have any of the above side effects or any other side effects that <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">worry</span> you while using zolpidem tartrate extended-release tablets.</span></p>
<p><span class="Bold">The most common side effects of zolpidem tartrate extended-release tablets are:</span></p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></li>
<li><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span></li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></li>
<li>You may still feel drowsy the next day after taking zolpidem tartrate extended-release tablets. <span class="Bold">Do not drive or do other dangerous activities after taking zolpidem tartrate extended-release tablets until you feel fully awake.</span>
</li>
</ul>
<p><span class="Bold">After you stop taking a sleep medicine, </span>you may have symptoms for 1 to 2 days such as: trouble sleeping, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, uncontrolled <span class="product-label-link" type="condition" conceptid="4136768" conceptname="Crying">crying</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span>, <span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attack</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, and stomach area <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.</p>
<p>These are not all the side effects of zolpidem tartrate extended-release tablets. Ask your doctor or pharmacist for more information.</p>
<p><span class="Bold">How should I store Zolpidem Tartrate Extended-Release Tablets?</span></p>
<ul class="Disc"><li>Store zolpidem tartrate extended-release tablets at 20Â° to 25Â°C (68Â° to 77Â°F) [See USP Controlled Room Temperature]</li></ul>
<ul class="Disc"><li><span class="Bold">Keep zolpidem tartrate extended-release tablets and all medicines out of reach of children.</span></li></ul>
<p><span class="Bold">General Information about Zolpidem Tartrate Extended-Release Tablets</span></p>
<ul class="Disc">
<li>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide.</li>
<li>Do not use zolpidem tartrate extended-release tablets for a condition for which it was not prescribed.</li>
<li>Do not share zolpidem tartrate extended-release tablets with other people, even if you think they have the same symptoms that you have. It may harm them and it is against the law.</li>
</ul>
<p>This Medication Guide summarizes the most important information about zolpidem tartrate extended-release tablets. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about zolpidem tartrate extended-release tablets that is written for healthcare professionals.Â  For more information about zolpidem tartrate extended-release tablets, call 1-800-432-8534 or visit www.Actavis.us.</p>
<p></p>
<p><span class="Bold">What are the ingredients in Zolpidem Tartrate Extended-Release Tablets, USP?</span></p>
<p><span class="Bold">Active Ingredient: </span>Zolpidem tartrate, USP</p>
<p><span class="Bold">Inactive Ingredients:Â  </span>anhydrous lactose, colloidal anhydrous silica, colloidal silicon dioxide, hypromellose, light anhydrous silicic acid, magnesium stearate, methacrylic acid copolymer, polyethylene glycol, povidone, silica, silicified microcrystalline cellulose, sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>, sodium lauryl sulfate, talc, tartaric acid, triethyl citrate, and titanium dioxide. Additionally, the 6.25 mg strength contains polyvinyl alcohol. The 12.5 mg strength also contains polydextrose, triacetin, and yellow iron oxide.</p>
<p>This Medication Guide has been approved by the U.S. Food and Drug Administration.</p>
<p>Manufactured by:</p>
<p>Actavis Elizabeth LLC</p>
<p>200 Elmora Avenue</p>
<p>Elizabeth, NJ 07207 USA</p>
<p>Revised â€“ February 2011</p>
<p>40-9104</p>
<p>(MG-41-1128)</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First"><span class="Bold">NDC 54569-6378-0</span></p>
<p>Packaged by:<br><span class="Bold">A-S Medication Solutions</span><br>Libertyville, IL 60048</p>
<br><div class="Figure"><img alt="6378-0.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a85400b5-1973-46bc-b092-681ac310f280&amp;name=6378-0.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-19"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First"><span class="Bold">NDC 54569-6231-1</span></p>
<p>Packaged by:<br><span class="Bold">A-S Medication Solutions</span><br>Libertyville, IL 60048</p>
<br><div class="Figure"><img alt="6231-1.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a85400b5-1973-46bc-b092-681ac310f280&amp;name=6231-1.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ZOLPIDEM TARTRATEÂ 		
					</strong><br><span class="contentTableReg">zolpidem tartrate tablet, film coated, extended release</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54569-6378(NDC:0228-3481)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CIVÂ Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ZOLPIDEM TARTRATE</strong> (ZOLPIDEM) </td>
<td class="formItem">ZOLPIDEM TARTRATE</td>
<td class="formItem">6.25Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOLS</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TARTARIC ACID</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">BICARBONATE</span></strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POVIDONE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>METHACRYLIC ACID - METHYL METHACRYLATE COPOLYMER (1:1)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TRIETHYL CITRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYVINYL ALCOHOL</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (BI-CONVEX) </td>
<td class="formLabel">Size</td>
<td class="formItem">7mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">A2</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54569-6378-0</td>
<td class="formItem">20  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA078179</td>
<td class="formItem">10/13/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ZOLPIDEM TARTRATEÂ 		
					</strong><br><span class="contentTableReg">zolpidem tartrate tablet, film coated, extended release</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54569-6231(NDC:0228-3482)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CIVÂ Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ZOLPIDEM TARTRATE</strong> (ZOLPIDEM) </td>
<td class="formItem">ZOLPIDEM TARTRATE</td>
<td class="formItem">12.5Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOLS</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TARTARIC ACID</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">BICARBONATE</span></strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POVIDONE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>METHACRYLIC ACID - METHYL METHACRYLATE COPOLYMER (1:1)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TRIETHYL CITRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYDEXTROSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TRIACETIN</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (BI-CONVEX) </td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">A1</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54569-6231-0</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54569-6231-1</td>
<td class="formItem">20  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA078179</td>
<td class="formItem">06/07/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>A-S Medication Solutions LLC
							(830016429)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">A-S Medication Solutions LLC</td>
<td class="formItem"></td>
<td class="formItem">830016429</td>
<td class="formItem">repack(54569-6378, 54569-6231)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 5/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>aaceea69-9ee0-48cc-9d96-9c51764baa0e</div>
<div>Set id: a85400b5-1973-46bc-b092-681ac310f280</div>
<div>Version: 1</div>
<div>Effective Time: 20130531</div>
</div>
</div>Â <div class="DistributorName">A-S Medication Solutions LLC</div></p>
</body></html>
